Ionis Pharmaceuticals: FDA Priority Review for Zilganersen Boosts Investment Outlook
Ionis Pharmaceuticals received a significant boost this week with the FDA’s acceptance of its New Drug Application for zilganersen, an investigational RNA-targeted therapy for Alexander disease. This Priority Review designation, ... Read More